Illumen Therapeutics Inc.
The University of Colorado Connection
Illumen Therapeutics is pursuing a cancer treatment moonshot, developing PARN Inhibitor drugs to increase functional p53, the 'Guardian of the Genome,' to treat aggressive cancers. Dysregulation of p53, a tumor suppressor protein, is the hallmark of nearly all cancers. Drugging p53 has been considered the Holy Grail of cancer drug development. The company is the first to pursue this novel, promising therapeutic strategy of inhibiting PARN to increase functional p53 to treat wild-type p53 aggressive cancers. PARN as a target and the therapeutic strategy of inhibiting PARN to increase functional p53 was discovered by Roy Parker (CU Boulder Biochemistry, BioFrontiers Institute).
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech, Therapeutics
- Funding Round: Seed
- Contact for Investment Inquiries: Bob Blomquist , CEO, bob@IllumenTx.com
In the News
- Colorado BioScience Association announces eight CU Boulder companies will present at 2026 Rocky Mountain Life Sciences Investor & Partnering Conference (2026, CBSA)
- CU Boulder pre-seed investment fuels cancer ‘moonshot’ spinout Illumen Therapeutics (2026)
- CU Boulder hosts showcases highlighting breakthrough innovations and investment-ready ventures (2025)
- Six CU Boulder startups selected to present at the Rocky Mountain Life Science Investor Conference (2024, CBSA)
Venture Partners Programs
- Pre-Seed Investment (2026)
- Destination Startup (2025)
- Starting Blocks Customer Discovery Workshop (2024)
- Lab Venture Challenge (2019)
- Intellectual Property Management (2023)
Technology Development Funding
U.S. National Institutes of Health (NIH), Howard Hughes Medical Institute
This page was last updated on April 6, 2026. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor eNewsletter
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.